Adicet Bio, Inc. entered into an Underwriting Agreement for an underwritten public offering of common stock and pre-funded warrants, with estimated net proceeds of $91.8 million. They also announced their preliminary financial data for the year ended December 31, 2023, with $159.7 million of cash and cash equivalents.